2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injuryQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2021
Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR)
Ordovas KG, Baldassarre LA, Bucciarelli-Ducci C, Carr J, Fernandes JL, Ferreira VM, Frank L, Mavrogeni S, Ntusi N, Ostenfeld E, Parwani P, Pepe A, Raman SV, Sakuma H, Schulz-Menger J, Sierra-Galan LM, Valente AM, Srichai MB. Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR). Journal Of Cardiovascular Magnetic Resonance 2021, 23: 52. PMID: 33966639, PMCID: PMC8108343, DOI: 10.1186/s12968-021-00746-z.Peer-Reviewed Original ResearchConceptsCardiovascular magnetic resonanceCardiovascular diseaseFemale patientsPosition statementHeart diseaseCancer therapy-related cardiac dysfunctionClinical scenariosStable ischemic heart diseaseUse of CMRAcute coronary syndromeSystemic rheumatic diseasesIschemic heart diseaseBicuspid aortic valveCongenital heart diseaseSpecific clinical scenariosMagnetic resonanceAortic syndromeCoronary syndromePeripartum cardiomyopathyCardiac dysfunctionRheumatic diseasesClinical evidenceAortic valveVascular disordersClinical care
2016
Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease
Baldassarre LA, Raman SV, Min JK, Mieres JH, Gulati M, Wenger NK, Marwick TH, Bucciarelli-Ducci C, Merz C, Itchhaporia D, Ferdinand KC, Pepine CJ, Walsh MN, Narula J, Shaw LJ, Committee A. Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease. JACC Cardiovascular Imaging 2016, 9: 421-435. PMID: 27056162, PMCID: PMC5486953, DOI: 10.1016/j.jcmg.2016.01.004.Peer-Reviewed Original ResearchConceptsIschemic heart diseaseHeart diseaseSymptoms of IHDSymptomatic ischemic heart diseaseStable ischemic heart diseasePotential therapeutic strategyCardiovascular deathSymptomatic womenIHD riskWorse outcomesContemporary imagingTherapeutic strategiesNoninvasive imagingRisk predictionWomenImaging targetsDiseaseMajor determinantFunctional differencesImagingMale counterpartsPatientsSymptoms